

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA fremanezumab for preventing migraine

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During the scoping process, it was highlighted that migraine is more common in women than in men, and more common in people of working age.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

Issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal. The committee will appraise fremanezumab for the population in its marketing authorisation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Jasdeep Hayre

Date: 22/10/2018